Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17083745 | 0.88 | FAAH (0.40) | CYP3A4ALDH1A1NPC1FAAHDPP4 | |
| SCHEMBL584795 | 0.79 | GNAI3 (0.50) | NAMPTCYP3A4CYP2C9ALDH1A1NPC1 | |
| SCHEMBL22919353 | 0.78 | EPHX2 (0.49) | ALDH1A1NPC1 | |
| SCHEMBL14009820 | 0.77 | NAMPT (0.42) | NAMPTCYP3A4CYP2C9ALDH1A1NPC1 | |
| SCHEMBL5010502 | 0.77 | NAMPT (0.38) | NAMPTPDK2 | |
| SCHEMBL21888398 | 0.76 | HCRTR2 (0.43) | NAMPTCYP3A4CYP2C9ALDH1A1NPC1 | |
| SCHEMBL4754522 | 0.76 | NAMPT (0.44) | NAMPTCYP3A4CYP2C9ALDH1A1NPC1 | |
| SCHEMBL4754539 | 0.76 | ALDH1A1 (0.38) | NAMPTALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL8487332 | 0.75 | ATM (0.48) | NAMPTCYP3A4CYP2C9ALDH1A1DPP4 | |
| SCHEMBL7292087 | 0.75 | NPC1 (0.47) | NAMPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | claimed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | claimed |
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | NAMPT 4382/4885CYP3A4 3670/4885CYP2C9 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.